医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Mead Johnson Nutrition Reaffirms Commitment to China Consumers

2013年07月03日 AM01:55
このエントリーをはてなブックマークに追加


 

GLENVIEW, Ill.

Mead Johnson Nutrition Company (NYSE: MJN) announced today that it is committed to providing high-quality and safe products at a good value for consumers in China and throughout the world. The company is fully cooperating with the recently reported Chinese government antitrust review of resale prices in the infant formula market and will provide information in response to inquiries received from government officials.

This year marks the 20th anniversary of Mead Johnson’s manufacturing presence in China, and the company values its longstanding relationships with local suppliers, distributors and other business partners. The company also remains fully committed to its many programs supporting the local communities in which it operates.

About Mead Johnson

Mead Johnson, a global leader in pediatric nutrition, develops, manufactures, markets and distributes more than 70 products in over 50 markets worldwide. The company’s mission is to nourish the world’s children for the best start in life. The Mead Johnson name has been associated with science-based pediatric nutrition products for over 100 years. The company’s “Enfa” family of brands, including Enfamil® infant formula, is the world’s leading brand franchise in pediatric nutrition. For more information, visit meadjohnson.com.

CONTACT

Mead Johnson
Investors:
Kathy MacDonald, (847) 832-2182
kathy.macdonald@mjn.com
Media:
Christopher
Perille, (847) 832-2178
chris.perille@mjn.com

Related Posts Plugin for WordPress, Blogger...

同じカテゴリーの記事 

  • スミス・ディテクションのBioFlashが空中のCOVID-19を検出可能であることを実証
  • コロナ禍で生じたうつ病をいやす韓国産ペットケアロボット「ペディ」が人気
  • Korean Pet Care Robot PEDDY Gains Popularity to Relieve Pets’ Depression During COVID-19
  • Dr. Reddy’s Laboratories announces the launch of Fluphenazine Hydrochloride Tablets, USP in the U.S. Market
  • Boston Immune Technologies and Therapeutics and BeiGene Enter into an Exclusive Option and License Agreement to Develop Novel TNFR2 Antagonists